Revolution Medicines, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 3 | -$0.75 | -$0.75 | -$0.75 |
| Q2 2024 | 6 | -$0.77 | -$0.77 | -$0.77 |
| Q3 2024 | 4 | -$0.89 | -$0.89 | -$0.89 |
| Q4 2024 | 11 | -$1.13 | -$0.95 | -$1.00 |
| Q1 2025 | 6 | -$1.08 | -$0.95 | -$1.00 |
| Q2 2025 | 5 | -$1.03 | -$1.03 | -$1.03 |
| Q3 2025 | 5 | -$1.05 | -$1.05 | -$1.05 |
| Q4 2025 | 5 | -$1.08 | -$1.08 | -$1.08 |
| Q1 2026 | 2 | -$1.10 | -$1.10 | -$1.10 |
| Q2 2026 | 2 | -$1.07 | -$1.07 | -$1.07 |
| Q3 2026 | 2 | -$1.07 | -$1.07 | -$1.07 |
| Q4 2026 | 2 | -$1.09 | -$1.09 | -$1.09 |
Revolution Medicines, Inc. Earnings Date And Information
Revolution Medicines, Inc. last posted its earnings results on Wednesday, November 6th, 2024. The company reported $-0.94 earnings per share for the quarter, missing analysts' consensus estimates of $-0.89 by $0.05. The company had revenue of 0 for the quarter and had revenue of 11.58 M for the year. Revolution Medicines, Inc. has generated $-4 earnings per share over the last year ($-3.86 diluted earnings per share) and currently has a price-to-earnings ratio of -16.7. Revolution Medicines, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 24th, 2025 based on prior year's report dates.
Revolution Medicines, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/06/2024 | Q3 2024 | -$0.89 | -$0.94 | -0.05 | $346,154 | $0 |
| 08/07/2024 | Q2 2024 | -$0.77 | -$0.81 | -0.04 | $807,692 | $0 |
| 05/08/2024 | Q1 2024 | -$0.75 | -$0.70 | 0.05 | $0 | |
| 02/26/2024 | Q4 2023 | -$0.86 | -$1.14 | -0.28 | $742,000 | |
| 11/06/2023 | Q3 2023 | -$1.01 | -$0.99 | 0.02 | $750,000 | $0 |
| 08/08/2023 | Q2 2023 | -$0.83 | -$0.92 | -0.09 | $1.56 M | $3.82 M |
| 05/08/2023 | Q1 2023 | -$0.84 | -$0.62 | 0.22 | $7.01 M | |
| 02/27/2023 | Q4 2022 | -$0.84 | -$0.63 | 0.21 | $15.33 M | |
| 11/07/2022 | Q3 2022 | -$0.87 | -$0.87 | 0 | $6.34 M | $3.36 M |
| 08/09/2022 | Q2 2022 | -$0.87 | -$0.81 | 0.06 | $7.02 M | $9.12 M |
| 05/09/2022 | Q1 2022 | -$0.82 | -$0.77 | 0.05 | $7.58 M | |
| 02/28/2022 | Q4 2021 | -$0.65 | -$0.71 | -0.06 | $9.46 M | |
| 11/10/2021 | Q3 2021 | -$0.62 | -$0.72 | -0.1 | $8.70 M | $1.10 M |
| 08/11/2021 | Q2 2021 | -$0.55 | -$0.60 | -0.05 | $9.38 M | $8.70 M |
| 05/10/2021 | Q1 2021 | -$0.52 | -$0.53 | -0.01 | $10.13 M | |
| 03/02/2021 | Q4 2020 | -$0.37 | -$0.52 | -0.15 | $8.75 M | |
| 11/12/2020 | Q3 2020 | -$0.39 | -$0.42 | -0.03 | $14.24 M | $12.66 M |
| 08/10/2020 | Q2 2020 | -$0.34 | -$0.46 | -0.12 | $13.36 M | $10.03 M |
| 05/14/2020 | Q1 2020 | -$0.33 | -$0.67 | -0.34 | $11.55 M | |
| 03/30/2020 | Q4 2019 | -$0.40 | $12.09 M |
Revolution Medicines, Inc. Earnings: Frequently Asked Questions
-
When is Revolution Medicines, Inc.'s earnings date?
Revolution Medicines, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 24th, 2025 based off last year's report dates.
-
How can I listen to Revolution Medicines, Inc.'s earnings conference call?
The conference call for Revolution Medicines, Inc.'s latest earnings report can be listened to online.
-
How can I read Revolution Medicines, Inc.'s conference call transcript?
The conference call transcript for Revolution Medicines, Inc.'s latest earnings report can be read online.
-
How much revenue does Revolution Medicines, Inc. generate each year?
Revolution Medicines, Inc. (:RVMD) has a recorded annual revenue of $11.58 M.
-
How much profit does Revolution Medicines, Inc. generate each year?
Revolution Medicines, Inc. (:RVMD) has a recorded net income of $11.58 M. Revolution Medicines, Inc. has generated $-3.86 earnings per share over the last four quarters.
-
What is Revolution Medicines, Inc.'s price-to-earnings ratio?
Revolution Medicines, Inc. (:RVMD) has a price-to-earnings ratio of -16.7 and price/earnings-to-growth ratio is -6.75.
